An Immunotherapeutic Vaccine Originally Developed Against Leprosy Is Effective Not Only Against Leprosy But Also Against Tuberculosis, Ano-genital Warts and Some Cancers – A Potent Invigorator of Immune Response

G.P. Talwar1*, Kritika Sonar1, Jagdish C. Gupta1, S. Puruswani1, Sangeeta Bhaskar2, Amulya K. Panda2, Somesh Gupta1, Rashi Pangti3, Dipankar Nandi4, Taru Verma4 and Srabanti Rakshit4

Introduction

On this Easter Sunday, when I (GPT) am starting to write this manuscript, my thoughts go to the people who become victims to this malady, leprosy. It is a disfiguring disease to which luckily few (about 1% in India) fall victims. The causative organism, M. leprae was discovered in Norway about two hundred years back by Armauer Hansen. It can replicate rather slowly (doubling time is about 13 days) in a suitable host cell. It is a mycobacteria surrounded in mystery. In 1970, a team from World Health Organisation (WHO) headed by Dr. Howard Goodman visited me in the Biochemistry Department of the All India Institute of Medical Sciences, New Delhi which I was heading. They wanted me to take up the Headship of a WHO Research & Training Centre in Immunology for India and South East Asia. I was reluctant. They told me that India has the world’s largest number of Lepers in the world. Are we expecting Americans to come and solve this problem? This shocked and shamed me and so I signed the papers without delay.

I knew nearly nothing of leprosy. I spent the next two summer vacations along with two talented students, A.D. Krishnan and Vijaylaxmi Mehra, in a Danish Save The Children Leprosy Home in Orissa to investigate why people fall victims to this disease. This work is reported in several publications.

Abstract

Based on atypical cultivable non-pathogenic mycobacteria, a vaccine with immunoprophylactic cum immuno-therapeutic properties against leprosy was developed by us many years back. The gene sequence of Mw (code word) is now known and it has been named as Mycobacterium indicus pranii (MIP). Besides Leprosy, MIP has also remarkable capabilities for treatment of tuberculosis including category II, “Difficult to treat” tuberculosis. What is further impressive is its ability to cure ugly ano-genital warts. It has therapeutic action against Myelomas. MIP activated T cells and cytokines, particularly γ-interferon play a major role in action of MIP against cancer cells. Combination of MIP with cyclophosphamide improves anti-tumour activity.

MIP is a potent invigorator of immune responses and is being employed as an adjuvant in a potential Birth Control Vaccine against hCG, currently under development. MIP is approved by the Drugs Controller General of India & US FDA. It is licensed to a company for availability to public in India and elsewhere in the world. Very recently, a trial has been launched by CSIR, Ministry of Science and Technology on the utility of Mw (MIP) to cure those individuals who are infected with Corona and protect family members if possible by immuno-prophylaxis.

Key words: Mw, MIP, Immunotherapy, Immunoprophylaxis, Adjuvant

I J Infectious Disea; 2020 www.unisciencepub.com Volume 1 | Issue 2
of this work is also published [1]. The nature of the immune deficit of those falling victims to this disease is their inability to react to some key antigens of M. leprae. Their immune system is otherwise competent to react and prevent various other prevailing infections, such as cholera, typhoid, etc. An experiment whose results are summarized in Table 1, shows the inability of T cells from multibacillary lepromatous leprosy patients to react with M. leprae to generate signals blocking the multiplication of M. leprae in monocyte-derived macrophages, (indicated by the incorporation of 3H-thymidine), whereas the T cells from Tuberculoid (paucibacillary) leprosy patients are competent to generate signals limiting the multiplication of M.leprae.

Monocyte-derived macrophages as host cells for M. leprae and 3H-thymidine incorporation as a sensitive measurable experimental way to quantitate DNA synthesis as a prerequisite to multiplication was established with the help of my student A.D Krishnan [2]. Macrophages do not have apparently any defect; they can originate from either LL, TT leprosy patients or normal human beings. It is the T cells that make the difference. Those from multibacillary LL patients are unable to generate cytokines influencing the multiplication or inhibition of the multiplication of indwelling M. leprae. It may be mentioned that monocyte derived macrophages do not multiply in-vitro and do not incorporate any 3H-thymidine into their DNA. This key experiment reported in Table 1 illustrates the nature of defect in leprosy patients.

Table 1: Mycobacterial multiplication in cultivated macrophages derived from peripheral blood monocytes of Leprosy patients [2]

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Clinical status</th>
<th>CPM 3H-thymidine incorporated per 5x105 phagocytic cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Macrophages+</td>
<td>Lymphocytes+M. leprae</td>
</tr>
<tr>
<td>1</td>
<td>LL</td>
<td>36,458</td>
</tr>
<tr>
<td>2</td>
<td>LL</td>
<td>53,929</td>
</tr>
<tr>
<td>3</td>
<td>LL</td>
<td>52,354</td>
</tr>
<tr>
<td>4</td>
<td>TT</td>
<td>6,332</td>
</tr>
<tr>
<td>5</td>
<td>TT</td>
<td>32</td>
</tr>
<tr>
<td>6</td>
<td>TT</td>
<td>381</td>
</tr>
</tbody>
</table>

LL: Lepromatous multibacillary Leprosy
TT: Tuberculoid paucibacillary form of Leprosy

What was further encouraging was the lasting nature of this conversion from Lepromin negativity to Lepromin positivity. Dr. Chaudhary at the School of Tropical Medicine Kolkata, conducted investigations in 32 Drugs-cured leprosy patients. While multidrugs treatment had rendered them bacteria free, Drugs were unable to render them Lepromin positive. After immunization of these patients with autoclaved MIP, 20 of them became Lepromin positive [3] lessening their chance of getting the disease on re-exposure to M. leprae.

Figure 1: Conversion of lepromin status of Borderline lepromatous (BL)/Lepromatous (LL) patients treated with either MDT alone or MDT+ MIP [4]

Additive effect of MIP on slow responding patients to Drugs
Treatment with the multi-drug regime usually takes about 2 years or more for rendering BL, LL patients, bacteria free. Some patients are extremely slow responders. Fig. 2 shows two cases in whom immunization with MIP hastened significantly the recovery [5].

Figure 2: Synergistic effect of Mw vaccine in slow responders to drugs in 2 patients. In both, the Bacterial index started declining on immunization with vaccine [5].

Gene Sequencing of Mw (MIP)
Our work to find appropriate non-pathogenic cultivable mycobacteria was done on 16 atypical mycobacteria obtained from various collections. These were all coded. The one, which eventually came out as a worthy candidate for a vaccine was Mw. Having proved its worth, a decision was taken to
determine the gene sequence of Mw. This was done in three laboratories, headed by Prof. Seyed Hasnain, Prof Anil Tyagi and Prof Akhilesh Tyagi: Their findings are reported in [6, 7]. Being given, that it was hitherto an undescribed mycobacteria, it was named as *Mycobacterium indicus pranii* (MIP); Pran is my family name and NII is the National Institute of Immunology, of which I was the Founder Director and from where a lot of basic work and clinical trials were conducted. Fig. 3 gives an Atomic Force Microscopy perspective of MIP.

![Atomic Force Microscopic imaging of MIP](image)

**Figure 3:** Atomic Force Microscopic imaging of MIP

**Remarkable Effect of Employing MIP as Adjunct to Drugs for Treatment of Patients**

Immunization of patients with MIP in addition to the usual approved multidrug treatment hastened bacterial clearance and shortened the period of recovery. What was remarkable was the lack of blemishes and usually ugly lesions normally not cleared by Drugs alone. Fig. 4 shows few patients, who received MIP, besides the Drugs. On recovery many of them looked normal as if they never had leprosy, unlike leprosy patients treated with drugs alone.

![Some representative cases of LL/BL multibacillary patients treated with MDT plus Mw (Mycobacterium indicus pranii)](image)

**Figure 4:** Some representative cases of LL/BL multibacillary patients treated with MDT plus Mw (Mycobacterium indicus pranii) [8].
Launching of MIP (Mw) for Treatment and Prevention of Corona-19 Infection

Currently the entire world is besieged by infection with the Corona-19 virus causing enormous deaths in USA, Italy, Spain, Iran and many countries of the world. Many states in India, specially Maharashtra and Delhi have fairly high infections and deaths. No specific drug or vaccine exists for this infection. The Director General of Council of Scientific Research (CSIR), The Ministry of Science and Technology with the approval of concerned authorities has launched the use of autoclaved Mw (MIP) manufactured by M/s Cadila Pharma company to which it was licensed by me, when I was the Director of the National Institute of Immunology and renewed by the current Director Dr. Amulya Panda. They are selling several preparations of autoclaved MIP (Mw) under different names for various purposes. Their preparation marketed as Sepsivac is fairly effective for immuno-therapy of Gram-negative sepsis. This will be given to patients infected by Corona-19 with the hope that their recovery will be expedited. It will also be given to family members and contacts with the expectation that they do not become victims of this dreadful infection.

MIP, a potent Invigorator of Immune Responses

We developed a vaccine against human chorionic gonadotropin (hCG), which was astonishingly very effective in preventing pregnancy in sexually active fertile women without derangement of ovulation, hormonal profiles and menstrual regularity [9]. A genetically engineered version of this vaccine has now been prepared and passed on to M/s Bharat Biotech for manufacture under GMP conditions. This vaccine includes MIP as an adjuvant, which enhances substantially antibody response as is evident in Fig.5.

Figure 5: Enhancement of antibody response to hCGβ-LTB vaccine in Balb/c mice by MIP. Mice were immunized intra-muscularly with 2μg of the vaccine adsorbed on alum with or without MIP. Primary immunization consisted of 3 injections given at fortnightly intervals followed by a booster on day 60 or 120. The symbols represent the titres in a given mouse. Bars give the geometrical means [10].

Tuberculosis

Tuberculosis is a major disease in many parts of the world. A vaccine was developed by Drs Calmette and Guerin at Institut Pasteur Paris about 100 years back based on a Bacillus named after them Bacillus Calmette Guerin (BCG). BCG is employed in India (and elsewhere) for immunizing children. However it has genetic restrictions of response. It is effective somewhere and not effective elsewhere. Thus in India there is need to supplement BCG with additional immunization with another vaccine. Our work shows that combined or subsequent immunization of mice or guinea pigs with MIP enhances substantially protection against Mycobacterium tuberculosis (Fig.6).
Employment of MIP along with chemotherapy for treatment of TB

The current multi-drug regimen in operation includes rifampicin, isoniazid, pyrazinamide and ethambutol. It usually results in poor compliance, as these drugs have to be taken for a minimum of 6-9 months. Although, new cases of TB can be treated by currently available drugs but patients who default on therapy run risk of relapse and drug resistance. Multipronged strategy is needed to effectively eliminate the actively multiplying as well as persistent mycobacteria from the infected lungs.

During the course of M.tb infection, the Th1 response is suppressed and Th2 response gets enhanced which helps in the survival of M.tb and results in progression of disease. An immunotherapy strategy which could boost the Th1 immune response in M.tb infected patients can be effective in clearance of bacteria as it would act synergistically with chemotherapy. Efficacy of MIP as an adjunct to standard chemotherapy for TB was evaluated in animal models, given by aerosol or subcutaneous route. MIP-immunotherapy by aerosol route induced increased infiltration of antigen specific lymphocytes and macrophages in the M.tb infected lungs, which resulted in enhanced reduction of bacterial load in a synergistic way along with chemotherapy. Moreover, there was less pulmonary pathology as compared to ‘drugs only’ treated group [11]. In the late stage of ‘drugs+MIP immunotherapy’ treatment, a balance between inflammatory and suppressive immune response was observed, which controlled initial inflammatory reaction and helped in restoration of normal lung tissue. Recent study by our group suggests that autophagy induced by MIP plays an important role in reversal of phagosome maturation block in M.tb infected macrophages [12]. Combined results of different studies suggest that MIP can be potentially very useful in eliminating the persistent bacteria when given as adjunct to chemotherapy. MIP immunotherapy by intranasal route can play a crucial role in early induction of protective immune response in the lungs.

MIP as a booster in BCG vaccinated animals conferred higher protection

In many countries including India, BCG is given along with several other vaccines for immunization of children. BCG protects against childhood tuberculosis but is poorly effective in adults. Significant protection against paediatric TB has been observed after BCG vaccination in endemic areas. Prime-boost vaccination is the most practical strategy for control of TB. MIP shares a large number of antigens with M.tb as well as BCG and also has shown higher protection as compared to BCG in animal models of TB. With this background, efficacy of MIP was evaluated as a booster to BCG vaccine in guinea pigs. Booster of MIP enhanced the BCG induced immune response and resulted in higher protection as compared to ‘only BCG’ immunized group (Fig. 6). Reduced pulmonary pathology e.g. less number of lesions, cavities and hemorrhagic spots were observed in ‘BCG-MIP’ group as compared to unvaccinated or ‘only BCG’ groups (Fig. 7). MIP booster via aerosol route was more effective in providing protection as compared to subcutaneous route of booster immunization [13]. Th1 and Th17 cytokines were induced at higher level in infected lungs of ‘BCG-MIP’ group as compared to ‘only BCG’ group. Higher frequency of multifunctional T cells with high MFI for IFN-γ
and TNF-α were observed in the ‘BCG-MIP’ group after M.tb infection. Findings of the study demonstrated that MIP can be given as a booster to the BCG vaccine during childhood for efficient protection against TB.

**Table 2:** Outcome of the additive effect of MIP in comparison to MDT alone for therapy of Cat II “Difficult to treat” tuberculosis patients.

<table>
<thead>
<tr>
<th>Treatment Description</th>
<th>Cured</th>
<th>Cured (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIP + MDT (n =49)</td>
<td>48/49a</td>
<td>97.96</td>
</tr>
<tr>
<td>MDT alone (n=27)</td>
<td>21/27b</td>
<td>77.77</td>
</tr>
</tbody>
</table>

Notes: *One patient defaulter for 6 doses, sputum negative after intensive phase; bSix patients - No effect of therapy

**Abbreviations**

MIP : *Mycobacterium indicus pranii*

Mw : *Mycobacterium w*

MDT : Multidrug Therapy

This was a double blind, placebo controlled, multi-centric trial where MIP demonstrated significantly higher cure rate in “difficult to treat” cases i.e. those with high bacillary load, drug-resistance and/or with bilateral cavities. At 4 week after start of immunotherapy along with standard drugs, sputum culture conversion was observed in significantly higher number of patients (67.1%) given adjunct therapy of MIP as compared to the placebo (57%) group (p = 0.0002). Early sputum conversion in the MIP group suggested that it played an important role in the clearance of M.tb. This has important implications in controlling the spread of M.tb as live bacteria in the sputum are major contributors for high incidence of TB. Recently a Phase III, double-blind, placebo controlled clinical study has started to evaluate efficacy of MIP in preventing TB in healthy household contacts of pulmonary TB patients.

**MIP Clears Ugly Warts**

*Mycobacterium indicus pranii* (MIP) vaccine is promising for treatment of warts though the exact mechanism by which MIP acts is not known. It is postulated that MIP mounts a strong Th1 mediated immune response, and helps clear HPV, which otherwise evades immune response [15-17].

Patients of anogenital warts, were given MIP initially intradermaly in deltoid area of both sides followed two weeks later by weekly intralesional injections into warts. Complete clearance was seen in 8 out of 9 patients with time for complete clearance ranging from 2 to 12 weeks [16]. Fig 8 and 9 give representative photographs showing clearance of ano-genital warts by MIP.

**Figure 8:** Effect of MIP on ugly anogenital warts. (a) A patient with giant condylomata. (b) The lesions completely subsided with intralesional immunotherapy with MIP.

In one of the recently concluded clinical trial, MIP was given as an adjunct to chemotherapy in Cat II pulmonary TB patients (Table 2).
Complete clearance in 83% patients of extensive cutaneous warts was seen with MIP vaccine with a mean time of complete clearance of 9.7 weeks (Fig. 10) [17]. A study on 30 patients with cutaneous warts at difficult to treat sites were given intralesional Mw vaccine with complete resolution seen in 93.33% patients [18].

A study comparing intradermal Mw vaccine with intradermal purified protein derivative (PPD) of tuberculin antigen in patients of multiple warts showed that MIP vaccine was much more effective than PPD [19]. In 66 patients of refractory extragenital warts, cryotherapy was compared with intralesional MIP vaccine. MIP vaccine had an advantage over cryotherapy in the clearance of distant warts [20]. Immunotherapy with MIP vaccine has proved to be an effective treatment modality for cutaneous warts and has potential as a first line treatment.

**MIP as an anti-tumor agent**

Mycobacteria have been known to induce anti-tumor responses ever since the pioneering studies by William Coley and the roles of different mycobacteria are documented [21]. The efficacy of MIP as an anti-tumor agent has been observed in multiple systems. MIP reduces tumours caused by B16F10 melanoma cells. MIP treated mice display higher Th1 responses and lower number of regulatory T cells [22]. We observed that a single intra-dermal injection of MIP, in a dose dependent manner, reduces the subcutaneous growth of SP2/0 myeloma in vivo [23]. The i.d. route of injection is effective. Two cytokines, IL12 and IFNγ, play an important role for anti-tumor immunity [24]. Also, MIP treatment reduces IL6, a known pro-survival factor for tumors [25].

The role of T cells in anti-tumor responses is well recognized [26]. Stimulation of splenocytes from MIP-immunized mice with tumor lysates led to reduction of proliferation of tumor cells. Tumor antigens stimulated the proliferation of specific anti-tumor T cells which kill the tumor cells. Notably, this killing was dependent on CD8+ T cells and was tumor-specific. Also, stimulation of MIP-immunized splenocytes greatly increased the production of IL2 and IFNγ in response to tumor lysates. CD4+ T cells were found to be primarily responsible for the production of cytokines. The data demonstrated that MIP induces a Th1 priming environment which triggers the generation of anti-tumor T cells that boost immunity and reduce tumor cell growth (Fig. 11).

It was of interest to investigate the action of MIP on various tumours. For this purpose, the highly invasive EL4 thymoma tumour was employed. The role of IFNγ was investigated using C57BL/6 and Ifng−/− mice. Treatment with MIP reduced the growth of EL4 tumour cells; however, no decline was observed in mice lacking IFNγ (Fig. 11). These observations reveal the importance of IFNγ in mediating the anti-tumor action of MIP. The direct role of MIP-induced anti-tumor lymphocytes was addressed in NOD-SCID mice, which lack lymphocytes. Both Sp2/0 and EL4 tumors grew well in this mouse strain, the efficacy of MIP in reducing tumor growth was not observed [23].
The combination of MIP and cyclophosphamide is potent in lowering the growth of tumors in vivo. Intra-dermal injection of MIP stimulates anti-tumor specific CD4+ and CD8+ T cells to lower tumor growth. The combination of MIP and cyclophosphamide was highly efficient in lowering the growth of tumors. This combination therapy leads to high amounts of IL12p70 and IFNγ. On the other hand, low levels of IL6, TGFβ, IL1β and IL10 are seen. The synergistic treatment was effective for both Sp2/0 and EL4 tumor model systems, including administration at later stages of tumor development (http://www.google.com/patents/US8367075; United States Patent No. 8,367,075 B2). Overall, our laboratory at the Indian Institute of Science, Bangalore, has carried out atomic force imaging and studied mechanisms involved in the immunotherapeutic effects of MIP. We have shown the role of MIP in the induction of Th1 cytokines and the stimulation of anti-tumor CD4+ and CD8+ T cell responses. In addition, the efficacy of MIP together with cyclophosphamide in significantly reducing tumor growth in mice was observed. Further studies are required to identify the MIP encoded molecules that are responsible for the adjuvant efficacy of MIP in lowering tumors [28]. Studies are also required to evaluate and understand the mechanisms, e.g. roles of signalling and effector molecules [29, 30] by which MIP modulates immune responses and is beneficial to the host. Overall, these studies are likely to enhance our understanding of the host immune network and may improve the quality of life.

Declarations

Funding: The work reviewed in this article received research grants from the Indian Council of Medical Research and the Department of Biotechnology Government of India.

Conflicts of Interests: Authors have no conflicts of interest

References


